Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

The Washington University

Status and phase

Terminated

Phase 1

Conditions

Myelofibroses

Treatments

Procedure: Peripheral blood draw

Drug: Pevonedistat

Procedure: Skin biopsy

Drug: Ruxolitinib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03386214

IISR-2017-101916 (Other Identifier)

201802152

Details and patient eligibility

About

Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.

Enrollment

8 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of primary myelofibrosis or post-polycythemia vera/essential thrombocythemia myelofibrosis classified as high risk, intermediate-2 risk, or intermediate 1 risk by IPSS.
On treatment with ruxolitinib for at least 3 months and have been on a stable dose for at least 8 weeks and have not achieved a CR by IWG criteria.
At least 18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Adequate bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 500/mcL, and have not received any growth factor support for at least 4 weeks prior to screening
- Platelets ≥ 50,000/mcL
- Peripheral blood blasts ≤ 10%
- Albumin > 2.7 g/dL
- Total bilirubin ≤ institutional upper limit of normal (IULN); patients with Gilbert's syndrome may enroll if direct bilirubin ≤ 1.5 x IULN
- ALT and AST ≤ 2.5 x IULN
- Creatinine clearance ≥ 50 mL/min
Female patients who:
- Are postmenopausal for at least 1 year before the screening visit, OR
- Are surgically sterile, OR
- If they are of childbearing potential:
  - Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
  - Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
Male patients, even if surgically sterilized (ie, status postvasectomy), who:
- Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
- Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)

Exclusion criteria

History of allogeneic stem cell transplant.
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during the study period.
Received hydroxyurea therapy within 28 days (4 weeks) before the first dose of any study drug.
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug.
Currently receiving any other investigational agents.
Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of study drug. Clinically significant metabolic enzyme inducers are not permitted during the study.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat, ruxolitinib, or other agents used in the study.
Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.
Diagnosis or treated for another malignancy within 2 years before enrollment, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any time are not excluded if they have undergone resection.
Ongoing or active infection.
Known cardiopulmonary disease defined as:
- Unstable angina pectoris
- Congestive heart failure (NYHA class III or IV)
- Myocardial infarction within 6 months prior to first dose (patients who had ischemic heart disease such as ACS, MI, and/or revascularization more than 6 months prior to enrollment and who are without cardiac symptoms may enroll)
- Symptomatic cardiomyopathy
- Clinically significant cardiac arrhythmia
  - History of polymorphic ventricular fibrillation or Torsade de Pointes
  - Permanent atrial fibrillation (a fib), defined as continuous a fib for ≥ 6 months
  - Persistent a fib, defined as sustained a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening
  - Grade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g. pacemaker) or ablation. Patients with Paroxysmal a fib or < grade 3 a fib for a period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen.
  - Implantable cardioverter defibrillator
  - Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)
Clinically significant pulmonary hypertension requiring pharmacologic therapy
Uncontrolled coagulopathy or bleeding disorder.
Uncontrolled high blood pressure (i.e. systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg).
Prolonged rate corrected QT (QTc) interval ≥ 500 msec, calculated according to institutional guidelines.
Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography.
Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis.
Known hepatic cirrhosis or severe pre-existing hepatic impairment.
Known CNS involvement.
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Female patients who intend to donate eggs and male patients who intended to donate sperm during the course of this study or for 4 months after receiving the last dose of study treatment.
Female patients who are both lactating and breastfeeding or have positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug
Known HIV-positivity.
Chronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier.
Life-threatening illness unrelated to cancer.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

8 participants in 3 patient groups

Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib

Experimental group

Description:

* Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle. * Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol.

Treatment:

Procedure: Peripheral blood draw

Drug: Ruxolitinib

Drug: Pevonedistat

Procedure: Skin biopsy

Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib

Experimental group

Description:

Treatment:

Procedure: Peripheral blood draw

Drug: Ruxolitinib

Drug: Pevonedistat